Relative lipophilicities, solubilities, and structure-pharmacological considerations of 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase inhibitors pravastatin, lovastatin, mevastatin, and simvastatin.
暂无分享,去创建一个
A. Serajuddin | S. Ranadive | E. Mahoney | A T Serajuddin | S A Ranadive | E M Mahoney | Eileen M. Mahoney
[1] H. Mabuchi,et al. Reduction of serum cholesterol in heterozygous patients with familial hypercholesterolemia. Additive effects of compactin and cholestyramine. , 1983, The New England journal of medicine.
[2] D R Abernethy,et al. Pharmacokinetics, central nervous system uptake, and lipid solubility of propranolol, acebutolol, and sotalol. , 1984, Cardiology.
[3] J. D. Karkas,et al. Tissue selectivity of the cholesterol-lowering agents lovastatin, simvastatin and pravastatin in rats in vivo. , 1989, Biochemical and biophysical research communications.
[4] J. Hoeg,et al. 3-Hydroxy-3-methylglutaryl--coenzyme A reductase inhibitors in the treatment of hypercholesterolemia. , 1987, JAMA.
[5] M. L. Robinson,et al. An investigation of the comparative liposolubilities of β‐adrenoceptor blocking agents , 1981, The Journal of pharmacy and pharmacology.
[6] H. Pan,et al. Comparative Pharmacokinetics and Pharmacodynamics of Pravastatin and Lovastatin , 1990, Journal of clinical pharmacology.
[7] I. Chen,et al. The physiological disposition of lovastatin. , 1989, Drug metabolism and disposition: the biological fate of chemicals.
[8] S. Grundy. HMG-CoA reductase inhibitors for treatment of hypercholesterolemia. , 1988, The New England journal of medicine.
[9] D. Greenblatt,et al. Pharmacologic properties of acebutolol: relationship of hydrophilicity to central nervous system penetration. , 1985, American heart journal.
[10] R. Tanaka,et al. Tissue-selective acute effects of inhibitors of 3-hydroxy-3-methylglutaryl coenzyme A reductase on cholesterol biosynthesis in lens. , 1989, Journal of lipid research.
[11] A. Leo,et al. Partition coefficients and their uses , 1971 .
[12] Y Hata,et al. The effect of CS-514 on serum lipids and apolipoproteins in hypercholesterolemic subjects. , 1987, JAMA.
[13] H. Canzler,et al. COMPARISON BETWEEN SIMVASTATIN AND BEZAFIBRATE IN EFFECT ON PLASMA LIPOPROTEINS AND APOLIPOPROTEINS IN PRIMARY HYPERCHOLESTEROLAEMIA , 1988, The Lancet.
[14] S. Grundy,et al. HMG-CoA reductase inhibitors for hypercholesterolemia. , 1988, The New England journal of medicine.
[15] M. Bonati,et al. Correlation between n‐octanol/water partition coefficient and liquid chromatographic retention for caffeine and its metabolites, and some structure‐pharmacokinetic considerations , 1987, The Journal of pharmacy and pharmacology.
[16] Y. Tsujita,et al. CS-514, a competitive inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A reductase: tissue-selective inhibition of sterol synthesis and hypolipidemic effect on various animal species. , 1986, Biochimica et biophysica acta.
[17] R. Heel,et al. Lovastatin , 2012, Drugs.